Evaluation of the effectiveness of sarcosine to parental education management treatment on the symptoms of coping disorder

Evaluation of the effectiveness of adding sarcosine to PMT (parental education management) treatment on the symptoms of coping disorder

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211022052836N1

Enrollment

Registered

2022-06-13

Start date

2019-12-22

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oppositional Defiant Disorder. F91/3

Interventions

Intervention group: Sarcosine powder in the form of 0.3 g capsules with a dose of 0.03 g per kg daily for the patient.

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Girl and boy children aged 6 to 12 years who have been diagnosed with coping disorder by a psychiatrist based on the DSM-V. 2. Parents' consent to participate in the study

Exclusion criteria

Exclusion criteria: 1- Patients who do not want to continue participating in the study at any stage. 2- Patients who do not plan their medication according to the prescribed medication and do not take it accurately. 3- Patients for whom another diagnosis is made during the study.

Design outcomes

Primary

Measure	Time frame
Percentage of people with Oppositional Defiant Disorder. Timepoint: At the beginning of the study, 2, 6 and 12 weeks after treatment. Method of measurement: Inventory Oppositional defiant behavioral Questionnaire (ODBI) and Demographic Information Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojgan karahmadi

Esfahan University of Medical Sciences

karahmad@med.mui.ac.ir+98 31 3668 8466

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026